Identification of patients who may benefit from prophylactic immunotherapy after bone marrow transplantation for acute myeloid leukemia on the basis of lymphocyte recovery early after transplantation

Blood

Volumn 91, Issue 9, 1998, Pages 3481-3486

  Powles, Ray ^a   Singhal, Seema ^a   Treleaven, Jennifer ^a   Kulkarni, Samar ^a   Horton, Clive ^a   Mehta, Jayesh ^a,b  

^a ROYAL MARSDEN HOSPITAL   (United Kingdom)

^b UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; CYCLOSPORIN; MELPHALAN; METHOTREXATE;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LEUKEMIA; ADOLESCENT; ADULT; ARTICLE; BONE MARROW TRANSPLANTATION; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CHILD; FEMALE; GRAFT VERSUS HOST REACTION; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; LYMPHOCYTE COUNT; LYMPHOCYTE DEPLETION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RELAPSE; TREATMENT OUTCOME;

EID: 0032079672     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.v91.9.3481.3481_3481_3486     Document Type: Article

References (39)

1. Thomas ED, Buckner CD, Clift RA, Feter A, Johnson FL, Neiman PE, Sale GE, Sanders JE, Singer JW, Shulman H, Storb R, Weiden PL: Marrow transplantation for acute nonlymphoblastic leukemia in first remission. N Engl J Med 301:597, 1979
2. Powles RL, Morgenstern G, Clink HM, Medley D, Bandini G, Lumley H, Watson JG, Lawson D, Spence D, Barrett A, Jameson B, Lawler S, Kay HE, McElwain TJ: The place of bone-marrow transplantation in acute myelogenous leukaemia. Lancet 1:1047, 1980
3. Helenglass G, Powles RL, McElwain TJ, Lakhani A, Milan S, Gore M, Nandi A, Zuiable A, Perren T, Forgeson G, Treleaven J, Hamilton CJ, Millar J: Melphalan and total body irradiation (TBI) versus cyclophosphamide and TBI as conditioning for allogeneic matched sibling bone marrow transplants for acute myeloblastic leukaemia in first remission. Bone Marrow Transplant 3:21, 1988
4. Geller RB, Saral R, Piantadosi S, Zahurak M, Vogelsang GB, Wingard JR, Ambinder RF, Beschorner WB, Braine HG, Burns WH, Hess AD, Jones RJ, May WS, Rowley SD, Wagner JE, Yeager AM, Santos GW: Allogeneic bone marrow transplantation after high-dose busulfan and cyclophosphamide in patients with acute nonlymphocytic leukemia. Blood 73:2209, 1989
5. Clift RA, Buckner CD, Appelbaum FR, Beannan SI, Petersen FB, Fisher LD, Anasetti C, Beatty P, Bensinger WI, Doney K, Hill RS, McDonald GB, Martin P, Sanders J, Singer J, Stewart P, Sullivan KM, Witherspoon R, Storb R, Hansen JA, Thomas ED: Allogeneic marrow transplantation in patients with acute myeloid leukemia in first remission: A randomized trial of two irradiation regimens. Blood 76:1867, 1990
6. Copelan EA, Biggs JC, Thompson JM, Crilley P, Szer J, Klein JP, Kapoor N, Avalos BR, Cunningham I, Atkinson K, Downs K, Harmon GS, Daly MB, Brodsky I, Bulova SI, Tutschka PJ: Treatment for acute myelocytic leukemia with allogeneic bone marrow transplantation following preparation with BuCy2. Blood 78:838, 1991
7. Blaise D, Maraninchi D, Archimbaud E, Reiffers J, Devergie A, Jouet JP, Milpied N, Attai M, Michallet M, Ifrah N, Kuentz M, Dauriac C, Bordigoni P, Gratecos N, Guilhot F, Guyotat D, Gouvernet J, Gluckman E: Allogeneic bone marrow transplantation for acute myeloid leukemia in first remission: A randomized trial of a busulfan-Cytoxan versus Cytoxan-total body irradiation as preparative regimen: A report from the Group d'Etudes de la Greffe de Moelle Osseuse. Blood 79:2578, 1992
8. Snyder DS, Chao NJ, Amylon MD, Taguchi J, Long GD, Negrin RS, Nademanee AP, O'Donnell MR, Schmidt GM, Stein AS, Parker PM, Smith EP, Stepan DE, Molina A, Lipsett JA, Hoppe RT, Niland JC, Dagis AC, Wong RM, Forman SJ, Blume KG: Fractionated total body irradiation and high-dose etoposide as a preparatory regimen for bone marrow transplantation for 99 patients with acute leukemia in first complete remission. Blood 82:2920, 1993
9. Cassileth PA, Lynch E, Mines JD, Oken MM, Mazza JJ, Bennett JM, McGlave PB, Edelstein M, Harrington DP, O'Connell MJ: Varying intensity of postremission therapy in acute myeloid leukemia. Blood 79:1924, 1992
10. Ringdén O, Horowitz MM, Sondel P, Gale RP, Biggs JC, Champlin RE, Deeg HJ, Dicke K, Masaoka T, Powles RL, Rimm AA, Rozman C, Sobocinski KA, Speck B, Zwaan F, Bortin MM: Methotrexate, cyclosporine, or both to prevent graft-versus-host disease after HLA-identical sibling bone marrow transplants for early leukemia? Blood 81:1094, 1993
11. Ljungman P, De Witte T, Verdonck L, Gahrton G, Freycon F, Gravett P, McCann S, Morgenstern HG, Nikoskelainen J, Powles R, Proctor SJ, Volin L, Zwaan F, Gratwohl A: Bone marrow transplantation for acute myeloblastic leukaemia: an EBMT Leukaemia Working Party prospective analysis from HLA-typing. Br J Haematol 84:61, 1993
12. Fagioli F, Bacigalupo A, Frassoni F, Van Lint MT, Occhini D, Gualandi F, Lamparelli T, Clavio M, Vitale V, Sogno G, Castoldi GL, Marmont AM: Allogeneic bone marrow transplantation for acute myeloid leukemia in first complete remission: The effect of FAB classification and GVHD prophylaxis. Bone Marrow Transplant 13:247, 1994
13. Weaver CH, Clift RA, Deeg HJ, Storb R, Appelbaum FR, Bensinger W, Doney K, Hansen JA, Martin PO, Sanders J, Sullivan KM, Thomas ED, Singer J, Witherspoon R, Buckner CD: Effect of graft-versus-host disease prophylaxis on relapse in patients transplanted for acute myeloid leukemia. Bone Marrow Transplant 14:885, 1994
14. Gale RP, Horowitz MM, Weiner RS, Ash RC, Atkinson K, Babu R, Dicke KA, Klein JP, Lowenberg B, Reiffers J, Rimm AA, Rowlings PA, Sandberg AA, Sobocinski KA, Veum-Stone J, Bortin MM: Impact of cytogenetic abnormalities on outcome of bone marrow transplants in acute myelogenous leukemia in first remission. Bone Marrow Trans-plant 16:203, 1995
15. Mehta J, Powles R, Treleaven J, Horton C, Tait D, Meller S, Pinkerton CR, Middleton G, Eisen T, Singhal S: Long-term follow-up of patients undergoing allogeneic bone marrow transplantation for acute myeloid leukemia in first complete remission after cyclophosphamide-total body irradiation and cyclosporine. Bone Marrow Transplant 18:741, 1996
16. Mehta J, Powles R, Treleaven J, Horton C, Meller S, Pinkerton CR, Singhai S: Outcome of acute leukemia relapsing after bone marrow transplantation: Utility of second transplants and adoptive immunotherapy. Bone Marrow Transplant 19:709, 1997
17. Mehta J, Powles R, Treleaven J, Kulkarni S, Singhal S: Induction of graft-versus-host disease as immunotherapy of leukemia relapsing after allogeneic transplantation: Single-center experience of 32 adult patients. Bone Marrow Transplant 20:129, 1997
18. Mehta J: Graft-versus-leukemia reactions in clinical bone marrow transplantation. Leuk Lymphoma 10:427, 1993
19. Sullivan KM, Storb R, Buckner CD, Fefer A, Fisher L, Weiden PL, Witherspoon RP, Appelbaum FR, Banaji M, Hansen J, Martin P. Sanders JE, Singer J, Thomas ED: Graft-versus-host disease as adoptive immunotherapy in patients with advanced hematologic neoplasms. N Engl J Med 320:828, 1989
20. Naparstek E, Or R, Nagler A, Cividalli G, Engelhard D, Aker M, Gimon Z, Manny N, Sacks T, Tochner Z, Weiss L, Samuel S, Brautbar C, Hale G, Waldmann H, Steinberg SM, Slavin S: T-cell-depleted allogeneic bone marrow transplantation for acute leukaemia using Campath-1 antibodies and post-transplant administration of donor's peripheral blood lymphocytes for prevention of relapse. Br J Haematol 89:506, 1995
21. Meyers JD, Flournoy N, Sanders JE, McGuffin RW, Newton BA, Fisher LD, Lum LG, Appelbaum FR, Doney K, Sullivan KM, Storb R, Buckner CD, Thomas ED: Prophylactic use of human leukocyte Interferon after allogeneic marrow transplantation. Ann Intern Med 107:809, 1987
22. Soiffer RJ, Murray C, Gonin R, Ritz J: Effect of low-dose interleukin-2 on disease relapse after T-cell-depleted allogeneic bone marrow transplantation. Blood 84:964, 1994
23. Aschan J, Ringden O, Andstrom E, Ljungman P, Lonnqvist B, Remberger M: Individualized prophylaxis against graft-versus-host disease in leukemic marrow transplant recipients. Bone Marrow Transplant 14:79, 1994
24. Powles R, Milan S, Horton C, Singhal S, Treleaven J, Mehta J: A prospective haemato-oncology patient database: Structure and description. Bone Marrow Transplant 17:S140, 1996 (suppl 1)
25. Powles R, Milan S, Horton C, Singhal S, Treleaven J, Mehta J: A prospective haemato-oncology patient database for use in routine care and clinical research. Bone Marrow Transplant 17:S55, 1996 (suppl 1)
26. Singhal S, Powles R, Kulkarni S, Treleaven J, Saso R, Long S, Rowland A, Millar B, Shepherd V, Cabrai S, Mehta J: Comparison of cell yields in a single-center, double-blind, randomized study of allogeneic marrow versus blood stem cell transplantation. Blood 90:592a, 1997 (suppl 1)
27. Singhal S, Powles R, Treleaven J, Horton C, Mehta J: Melphalan alone prior to allogeneic bone marrow transplantation from HLA-identical sibling donors for hematologic malignancies: Alloengraftment with potential preservation of fertility. Bone Marrow Transplant 18: 1049, 1996
28. Mehta J, Powles RL, Mitchell P, Rege K, De Lord C, Treleaven J: Graft failure after bone marrow transplantation from unrelated donors using busulphan and cyclophosphamide for conditioning. Bone Marrow Transplant 13:583, 1994
29. Hale G, Waldmann H: Control of graft-versus-host disease and graft rejection by T cell depletion of donor and recipient with Campath-1 antibodies. Results of matched sibling transplants for malignant diseases. Bone Marrow Transplant 13:597, 1994
30. Mehta J, Powles R, Singhal S, Horton C, Hamblin M, Zomas A, Saso R, Treleaven J: Transfusion requirements after bone marrow transplantation from HLA-identical siblings: Effects of donor-recipient ABO incompatibility. Bone Marrow Transplant 18:151, 1996
31. Mehta J, Powles R, Singhal S, Horton C, Middleton G, Eisen T, Meller S, Pinkerton CR, Treleaven J: Early identification of patients at risk of death due to infections, hemorrhage, or graft failure after allogeneic bone marrow transplantation on the basis of the leukocyte counts. Bone Marrow Transplant 19:349, 1997
32. Mehta J, Powles R, Horton C, Treleaven J, Singhal S: Leukocyte recovery and early treatment-related mortality after bone marrow transplantation. Blood 89:4237, 1997
33. International Bone Marrow Transplant Registry: Effect of methotrexate on relapse after bone-marrow transplantation for acute lymphoblastic leukaemia. Lancet 1:535, 1989
34. Biaise D, Olive D, Michallet M, Marit G, Leblond V, Maraninchi D: Impairment of leukaemia-free survival by addition of interleukin-2-receptor antibody to standard graft-versus-host prophylaxis. Lancet 345:1144, 1995
35. Jiang YZ, Barrett AJ, Goldman JM, Mavroudis DA: Association of natural killer cell immune recovery with a graft-versus-leukemia effect independent of graft-versus-host disease following allogeneic bone marrow transplantation. Ann Hematol 74:1, 1997
36. Hancock J, Burgess M, Goulden N, Ferns V, Steward C, Potter M, Oakhill A: Prediction of relapse following unrelated BMT for childhood acute lymphoblastic leukaemia by serial analysis of early chimerism, Blood 88:268a, 1996 (suppl 1)
37. Samson D, Volin L, Schanz U, Bosi A, Gahrton G: Feasibility and toxicity of interferon maintenance therapy after allogeneic BMT for multiple myeloma: A pilot study of the EBMT. Bone Marrow Transplant 17:759, 1996
38. Mehta J, Powles R, Singhal S, Iveson T, Treleaven J, Catovsky D: Clinical and hematologic response of chronic lymphocytic and prolymphocytic leukemia persisting after allogeneic bone marrow transplantation with the onset of acute graft-versus-host disease: Possible role of graft-versus-leukemia. Bone Marrow Transplant 17: 371, 1996
39. Powles RL, Crowther D, Bateman CJ, Beard ME, McElwain TJ, Russell J, Lister TA, Whitehouse JM, Wrigley PF, Pike M, Alexander P, Fairley GH: Immunotherapy for acute myelogenous leukaemia. Br J Cancer 28:365, 1973